Skip to main content
SpringerLink
Log in

Clinical Trials for Opioid Use Disorder

  • Chapter
  • First Online:
Substance Use Disorders

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 258))

Abstract

This chapter describes recent clinical trials for opioid use disorder (OUD), an area that has rapidly accelerated in response to the opioid overdose crisis in the USA and newly appropriated funding. Trials involve a wide range of compounds including cannabinoids and psychedelics, new and existing compounds targeting domains emerging from addiction neuroscience, agents repurposed from other indications, and novel strategies including vaccines, enzymes, and other biologicals. In parallel, new formulations of existing compounds offer immediate promise, as do a variety of web-based interventions and smartphone-delivered apps. Trials focused on implementing existing effective interventions in mainstream healthcare settings, and others focused on special populations, e.g., adolescents, criminal justice, pregnant women, native Americans, etc., have the potential to vastly expand treatment in the near term. Given the range of ongoing and recent trials, this chapter is not intended to be an exhaustive review but rather to present an overview of approaches within the framework of the opioid treatment cascade and the context of current OUD pharmacotherapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Addy NA et al (2018) The L-type calcium channel blocker, isradipine, attenuates cue-induced cocaine-seeking by enhancing dopaminergic activity in the ventral tegmental area to nucleus accumbens pathway. Neuropsychopharmacology 43(12):2361–2372

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Akbarzadeh A et al (2009) J Pharmacol Toxicol 4(1):30–35

    Article  CAS  Google Scholar 

  • Auriacombe M, O’Brien CP, Tignol J (1994) Buprenorphine in the treatment of opiate dependence. Ann Med Interne (Paris) 145(Suppl 3):27

    Google Scholar 

  • Babalonis S et al (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 172:9–13

    Article  CAS  PubMed  Google Scholar 

  • Bachhuber MA et al (2014) Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. JAMA Intern Med 174(10):1668–1673

    Article  PubMed  PubMed Central  Google Scholar 

  • Bastiaens L, Galus J, Mazur C (2016) Abuse of gabapentin is associated with opioid addiction. Psychiatry Q 87(4):763–767

    Article  Google Scholar 

  • Bernardo A, Minghetti L (2006) PPAR-gamma agonists as regulators of microglial activation and brain inflammation. Curr Pharm Des 12(1):93–109

    Article  CAS  PubMed  Google Scholar 

  • Bisaga A et al (2015) The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug Alcohol Depend 154:38–45

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Blessing EM et al (2015) Cannabidiol as a potential treatment for anxiety disorders. Neurotherapeutics 12(4):825–836

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bonese KF et al (1974) Changes in heroin self-administration by a rhesus monkey after morphine immunisation. Nature 252(5485):708–710

    Article  CAS  PubMed  Google Scholar 

  • Bonnet U, Scherbaum N (2017) How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol 27(12):1185–1215

    Article  CAS  PubMed  Google Scholar 

  • Bremer PT et al (2016) Combatting synthetic designer opioids: a conjugate vaccine ablates lethal doses of fentanyl class drugs. Angew Chem Int Ed Engl 55(11):3772–3775

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Brown TK, Alper K (2018) Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse 44(1):24–36

    Article  PubMed  Google Scholar 

  • Bruchas MR, Land BB, Chavkin C (2010) The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res 1314:44–55

    Article  CAS  PubMed  Google Scholar 

  • Butelman ER, Yuferov V, Kreek MJ (2012) kappa-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci 35(10):587–596

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Buydens-Branchey L, Branchey M, Reel-Brander C (2005) Efficacy of buspirone in the treatment of opioid withdrawal. J Clin Psychopharmacol 25(3):230–236

    Article  CAS  PubMed  Google Scholar 

  • C Mash D (2018) Breaking the cycle of opioid use disorder with ibogaine. Am J Drug Alcohol Abuse 44(1):1–3

    Article  PubMed  Google Scholar 

  • Chattopadhyay S et al (2010) Tramadol versus clonidine in management of heroin withdrawal. Asian J Psychiatr 3(4):237–239

    Article  PubMed  Google Scholar 

  • Chou R et al (2017) Management of suspected opioid overdose with naloxone in out-of-hospital settings: a systematic review. Ann Intern Med 167(12):867–875

    Article  PubMed  Google Scholar 

  • Chu LF et al (2018) Ondansetron does not prevent physical dependence in patients taking opioid medications chronically for pain control. Drug Alcohol Depend 183:176–183

    Article  CAS  PubMed  Google Scholar 

  • Commons KG (2010) Neuronal pathways linking substance P to drug addiction and stress. Brain Res 1314:175–182

    Article  CAS  PubMed  Google Scholar 

  • Cooper ZD, Jones JD, Comer SD (2012) Glial modulators: a novel pharmacological approach to altering the behavioral effects of abused substances. Expert Opin Investig Drugs 21(2):169–178

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cooper ZD et al (2016) The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addict Biol 21(4):895–903

    Article  CAS  PubMed  Google Scholar 

  • Cooper ZD et al (2017) Effects of ibudilast on oxycodone-induced analgesia and subjective effects in opioid-dependent volunteers. Drug Alcohol Depend 178:340–347

    Article  CAS  PubMed  Google Scholar 

  • Cox S, Alcorn R (1995) Lofexidine and opioid withdrawal. Lancet 345(8962):1385–1386

    Article  CAS  PubMed  Google Scholar 

  • Crippa JA et al (2018) Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Front Immunol 9:2009

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • D’Onofrio G et al (2015) Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA 313(16):1636–1644

    Article  PubMed  PubMed Central  Google Scholar 

  • De Felipe C et al (1998) Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 392(6674):394–397

    Article  PubMed  Google Scholar 

  • de Guglielmo G et al (2015) PPARgamma activation attenuates opioid consumption and modulates mesolimbic dopamine transmission. Neuropsychopharmacology 40(4):927–937

    Article  PubMed  CAS  Google Scholar 

  • de Guglielmo G et al (2017) Pioglitazone attenuates the opioid withdrawal and vulnerability to relapse to heroin seeking in rodents. Psychopharmacology (Berl) 234(2):223–234

    Article  CAS  Google Scholar 

  • Dunn KE et al (2017) Efficacy of tramadol extended-release for opioid withdrawal: a randomized clinical trial. JAMA Psychiatry 74(9):885–893

    Article  PubMed  PubMed Central  Google Scholar 

  • Dupouy J et al (2017) Mortality associated with time in and out of buprenorphine treatment in french office-based general practice: a 7-year cohort study. Ann Fam Med 15(4):355–358

    Article  PubMed  PubMed Central  Google Scholar 

  • Fasinu PS et al (2016) Current status and prospects for cannabidiol preparations as new therapeutic agents. Pharmacotherapy 36(7):781–796

    Article  PubMed  Google Scholar 

  • Freynhagen R et al (2016) Pregabalin for the treatment of drug and alcohol withdrawal symptoms: a comprehensive review. CNS Drugs 30(12):1191–1200

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gadd CA et al (2003) Neurokinin-1 receptor-expressing neurons in the amygdala modulate morphine reward and anxiety behaviors in the mouse. J Neurosci 23(23):8271–8280

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Garbutt JC et al (2005) Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293(13):1617–1625

    Article  CAS  PubMed  Google Scholar 

  • George DT et al (2008) Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 319(5869):1536–1539

    Article  CAS  PubMed  Google Scholar 

  • Gerak LR et al (2019) Effects of lorcaserin on reinstatement of responding previously maintained by cocaine or remifentanil in rhesus monkeys. Exp Clin Psychopharmacol 27(1):78–86

    Article  CAS  PubMed  Google Scholar 

  • Ghavimi H et al (2014) Pioglitazone prevents morphine antinociception tolerance and withdrawal symptoms in rats. Naunyn Schmiedebergs Arch Pharmacol 387(9):811–821

    Article  CAS  PubMed  Google Scholar 

  • Ghavimi H et al (2015) Acute administration of pioglitazone attenuates morphine withdrawal syndrome in rat: a novel role of pioglitazone. Drug Res (Stuttg) 65(3):113–118

    CAS  Google Scholar 

  • Gold MS (1993) Opiate addiction and the locus coeruleus. The clinical utility of clonidine, naltrexone, methadone, and buprenorphine. Psychiatr Clin North Am 16(1):61–73

    Article  CAS  PubMed  Google Scholar 

  • Gold MS et al (1979) Clonidine detoxification: a fourteen-day protocol for rapid opiate withdrawal. NIDA Res Monogr 27:226–232

    CAS  PubMed  Google Scholar 

  • Gold MS et al (1980a) Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment. JAMA 243(4):343–346

    Article  CAS  PubMed  Google Scholar 

  • Gold MS et al (1980b) Clonidine and opiate withdrawal. Lancet 2(8203):1078–1079

    Article  CAS  PubMed  Google Scholar 

  • Gonzalez-Cuevas G et al (2018) Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle. Neuropsychopharmacology 43(10):2036–2045

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gorodetzky CW et al (2017) A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. Drug Alcohol Depend 176:79–88

    Article  CAS  PubMed  Google Scholar 

  • Gowing L, Ali R, White JM (2009) Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst Rev 4:CD002021

    Google Scholar 

  • Gowing L et al (2017) Buprenorphine for managing opioid withdrawal. Cochrane Database Syst Rev 2:CD002025

    PubMed  Google Scholar 

  • Haasen C, Linden M, Tiberg F (2017) Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder. J Subst Abuse Treat 78:22–29

    Article  PubMed  Google Scholar 

  • Hah J et al (2018) Effect of perioperative gabapentin on postoperative pain resolution and opioid cessation in a mixed surgical cohort: a randomized clinical trial. JAMA Surg 153(4):303–311

    Article  PubMed  Google Scholar 

  • Hargreaves R (2002) Imaging substance P receptors (NK1) in the living human brain using positron emission tomography. J Clin Psychiatry 63(Suppl 11):18–24

    CAS  PubMed  Google Scholar 

  • Hasanein P, Shakeri S (2014) Pregabalin role in inhibition of morphine analgesic tolerance and physical dependency in rats. Eur J Pharmacol 742:113–117

    Article  CAS  PubMed  Google Scholar 

  • Hser YI et al (2016) Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction 111(4):695–705

    Article  PubMed  PubMed Central  Google Scholar 

  • Addiction Reserach Center. https://archives.drugabuse.gov/news-events/nida-notes/1995/12/history-addiction-research-center

  • Present opioid crisis. https://www.drugabuse.gov/drugs-abuse/opioids/opioid-overdose-crisis; https://www.hhs.gov/opioids/about-the-epidemic/index.html

  • HEAL initiative. https://www.nih.gov/research-training/medical-research-initiatives/heal-initiative/heal-initiative-research-plan

  • Hurd YL, O’Brien CP (2018) Molecular genetics and new medication strategies for opioid addiction. Am J Psychiatry 175(10):935–942

    Article  PubMed  PubMed Central  Google Scholar 

  • Hurd YL et al (2015) Early phase in the development of cannabidiol as a treatment for addiction: opioid relapse takes initial center stage. Neurotherapeutics 12(4):807–815

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hurd YL et al (2019) Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: a double-blind randomized placebo-controlled trial. Am J Psychiatry:appiajp201918101191

    Google Scholar 

  • Hutchinson MR et al (2008) Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia. Brain Behav Immun 22(8):1178–1189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Iffland K, Grotenhermen F (2017) An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 2(1):139–154

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Javadi S et al (2013) Pioglitazone potentiates development of morphine-dependence in mice: possible role of NO/cGMP pathway. Brain Res 1510:22–37

    Article  CAS  PubMed  Google Scholar 

  • Jicha CJ et al (2015) Safety of oral dronabinol during opioid withdrawal in humans. Drug Alcohol Depend 157:179–183

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Johnston IN et al (2004) A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 24(33):7353–7365

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jones JD et al (2013) Opioid-like effects of the neurokinin 1 antagonist aprepitant in patients maintained on and briefly withdrawn from methadone. Am J Drug Alcohol Abuse 39(2):86–91

    Article  PubMed  PubMed Central  Google Scholar 

  • Jones JD et al (2016) The effects of pioglitazone, a PPARgamma receptor agonist, on the abuse liability of oxycodone among nondependent opioid users. Physiol Behav 159:33–39

    Article  CAS  PubMed  Google Scholar 

  • Jones JD et al (2018) The PPARgamma agonist pioglitazone fails to alter the abuse potential of heroin, but does reduce heroin craving and anxiety. J Psychoactive Drugs 50(5):390–401

    Article  PubMed  PubMed Central  Google Scholar 

  • Jovaisa T et al (2006) Effects of ketamine on precipitated opiate withdrawal. Medicina (Kaunas) 42(8):625–634

    Google Scholar 

  • Kammerer N et al (2012) Pregabalin for the reduction of opiate withdrawal symptoms. Psychiatr Prax 39(7):351–352

    Article  PubMed  Google Scholar 

  • Kaplan JL et al (1999) Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose. Ann Emerg Med 34(1):42–50

    Article  CAS  PubMed  Google Scholar 

  • Kathmann M et al (2006) Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol 372(5):354–361

    Article  CAS  PubMed  Google Scholar 

  • Kheirabadi GR et al (2008) Effect of add-on gabapentin on opioid withdrawal symptoms in opium-dependent patients. Addiction 103(9):1495–1499

    Article  PubMed  Google Scholar 

  • Kim HK, Nelson LS (2015) Reducing the harm of opioid overdose with the safe use of naloxone: a pharmacologic review. Expert Opin Drug Saf 14(7):1137–1146

    Article  CAS  PubMed  Google Scholar 

  • Kinlock TW et al (2007) A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend 91(2–3):220–227

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Kohut SJ, Bergman J (2018) Lorcaserin decreases the reinforcing effects of heroin, but not food, in rhesus monkeys. Eur J Pharmacol 840:28–32

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Koob GF (2013) Addiction is a reward deficit and stress surfeit disorder. Front Psychiatry 4:72

    Article  PubMed  PubMed Central  Google Scholar 

  • Koob GF, Volkow ND (2016) Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry 3(8):760–773

    Article  PubMed  PubMed Central  Google Scholar 

  • Koob GF et al (2014) Addiction as a stress surfeit disorder. Neuropharmacology 76(Pt B):370–382

    Article  CAS  PubMed  Google Scholar 

  • Kovacs GL, Sarnyai Z, Szabo G (1998) Oxytocin and addiction: a review. Psychoneuroendocrinology 23(8):945–962

    Article  CAS  PubMed  Google Scholar 

  • Kreek MJ (2000) Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci 909:186–216

    Article  CAS  PubMed  Google Scholar 

  • Kreek MJ, Vocci FJ (2002) History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat 23(2):93–105

    Article  PubMed  Google Scholar 

  • Kreek MJ, LaForge KS, Butelman E (2002) Pharmacotherapy of addictions. Nat Rev Drug Discov 1(9):710–726

    Article  CAS  PubMed  Google Scholar 

  • Krieter P et al (2019) Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose. J Pharmacol Exp Ther 371(2):409–415

    Article  CAS  Google Scholar 

  • Krupitsky E et al (2002) Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. J Subst Abuse Treat 23(4):273–283

    Article  PubMed  Google Scholar 

  • Krupitsky EM et al (2007) Single versus repeated sessions of ketamine-assisted psychotherapy for people with heroin dependence. J Psychoactive Drugs 39(1):13–19

    Article  PubMed  Google Scholar 

  • Krupitsky E et al (2011) Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 377(9776):1506–1513

    Article  CAS  PubMed  Google Scholar 

  • Krupitsky EM et al (2016) A randomized single blind study of the efficacy of pregabalin in the treatment of opioid withdrawal syndrome. Zh Nevrol Psikhiatr Im S S Korsakova 116(7):29–36

    Article  CAS  PubMed  Google Scholar 

  • Kwako LE et al (2015) The neurokinin-1 receptor antagonist aprepitant in co-morbid alcohol dependence and posttraumatic stress disorder: a human experimental study. Psychopharmacology (Berl) 232(1):295–304

    Article  CAS  Google Scholar 

  • LaBelle CT et al (2016) Office-based opioid treatment with buprenorphine (OBOT-B): statewide implementation of the Massachusetts Collaborative Care Model in community health centers. J Subst Abuse Treat 60:6–13

    Article  PubMed  Google Scholar 

  • Ledeboer A et al (2007) Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 16(7):935–950

    Article  CAS  PubMed  Google Scholar 

  • Lee JD et al (2012) Buprenorphine-naloxone maintenance following release from jail. Subst Abus 33(1):40–47

    Article  PubMed  PubMed Central  Google Scholar 

  • Lee JD et al (2015) Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial. Addiction 110(6):1008–1014

    Article  PubMed  Google Scholar 

  • Lee JD et al (2016) Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med 374(13):1232–1242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lee JD et al (2018) Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet 391(10118):309–318

    Article  CAS  PubMed  Google Scholar 

  • Leong KC et al (2018) Oxytocin and rodent models of addiction. Int Rev Neurobiol 140:201–247

    Article  PubMed  PubMed Central  Google Scholar 

  • Liang D et al (2018) Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993-2014. Addiction 113(11):2060–2070

    Article  PubMed  PubMed Central  Google Scholar 

  • Ling W et al (2005) A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction 100(8):1090–1100

    Article  PubMed  PubMed Central  Google Scholar 

  • Ling W et al (2009) Buprenorphine tapering schedule and illicit opioid use. Addiction 104(2):256–265

    Article  PubMed  PubMed Central  Google Scholar 

  • Ling W et al (2011) Selective review and commentary on emerging pharmacotherapies for opioid addiction. Subst Abuse Rehabil 2:181–188

    Article  PubMed  PubMed Central  Google Scholar 

  • Lisdahl KM et al (2018) Adolescent brain cognitive development (ABCD) study: overview of substance use assessment methods. Dev Cogn Neurosci 32:80–96

    Article  PubMed  PubMed Central  Google Scholar 

  • Litjens RP, Brunt TM (2016) How toxic is ibogaine? Clin Toxicol (Phila) 54(4):297–302

    Article  CAS  Google Scholar 

  • Litten RZ et al (2015) Heterogeneity of alcohol use disorder: understanding mechanisms to advance personalized treatment. Alcohol Clin Exp Res 39(4):579–584

    Article  PubMed  Google Scholar 

  • Lofwall MR et al (2007) Modest opioid withdrawal suppression efficacy of oral tramadol in humans. Psychopharmacology (Berl) 194(3):381–393

    Article  CAS  Google Scholar 

  • Lofwall MR et al (2013) Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial. Drug Alcohol Depend 133(1):188–197

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lofwall MR et al (2016) Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. Drug Alcohol Depend 164:143–150

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Malcolm BJ, Polanco M, Barsuglia JP (2018) Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine. J Psychoactive Drugs 50(3):256–265

    Article  PubMed  Google Scholar 

  • Maldonado R, Girdlestone D, Roques BP (1993) RP 67580, a selective antagonist of neurokinin-1 receptors, modifies some of the naloxone-precipitated morphine withdrawal signs in rats. Neurosci Lett 156(1–2):135–140

    Article  CAS  PubMed  Google Scholar 

  • Mannangatti P et al (2017) Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward. Psychopharmacology (Berl) 234(4):695–705

    Article  CAS  Google Scholar 

  • Mattick RP et al (2014) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2:CD002207

    Google Scholar 

  • McDonald RD et al (2016) Extended-release naltrexone opioid treatment at jail reentry (XOR). Contemp Clin Trials 49:57–64

    Article  PubMed  PubMed Central  Google Scholar 

  • McNeely J et al (2016) Performance of the tobacco, alcohol, prescription medication, and other substance use (TAPS) tool for substance use screening in primary care patients. Ann Intern Med 165(10):690–699

    Article  PubMed  PubMed Central  Google Scholar 

  • Metz VE et al (2017) Effects of ibudilast on the subjective, reinforcing, and analgesic effects of oxycodone in recently detoxified adults with opioid dependence. Neuropsychopharmacology 42(9):1825–1832

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Morgan CJ et al (2013) Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav 38(9):2433–2436

    Article  PubMed  Google Scholar 

  • Murphy SM et al (2017) Cost-effectiveness of extended release naltrexone to prevent relapse among criminal justice-involved individuals with a history of opioid use disorder. Addiction 112(8):1440–1450

    Article  PubMed  PubMed Central  Google Scholar 

  • Murtra P et al (2000) Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature 405(6783):180–183

    Article  CAS  PubMed  Google Scholar 

  • Myhre M, Romundstad L, Stubhaug A (2017) Pregabalin reduces opioid consumption and hyperalgesia but not pain intensity after laparoscopic donor nephrectomy. Acta Anaesthesiol Scand 61(10):1314–1324

    Article  CAS  PubMed  Google Scholar 

  • Neelakantan H et al (2017) Lorcaserin suppresses oxycodone self-administration and relapse vulnerability in rats. ACS Chem Nerosci 8(5):1065–1073

    Article  CAS  Google Scholar 

  • Nielsen S et al (2016) Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev 5:CD011117

    Google Scholar 

  • No Authors Listed (2018) Once-monthly subcutaneous buprenorphine (Sublocade) for opioid use disorder. Med Lett Drugs Ther 60(1541):35–37

    Google Scholar 

  • Noller GE, Frampton CM, Yazar-Klosinski B (2018) Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse 44(1):37–46

    Article  PubMed  Google Scholar 

  • Olfson M et al (2018) Cannabis use and risk of prescription opioid use disorder in the United States. Am J Psychiatry 175(1):47–53

    Article  PubMed  Google Scholar 

  • Olson KM et al (2017) Novel molecular strategies and targets for opioid drug discovery for the treatment of chronic pain. Yale J Biol Med 90(1):97–110

    CAS  PubMed  PubMed Central  Google Scholar 

  • Placenza FM et al (2006) Effects of central neurokinin-1 receptor antagonism on cocaine- and opiate-induced locomotor activity and self-administration behaviour in rats. Pharmacol Biochem Behav 84(1):94–101

    Article  CAS  PubMed  Google Scholar 

  • Pravetoni M (2016) Biologics to treat substance use disorders: current status and new directions. Hum Vaccin Immunother 12(12):3005–3019

    Article  PubMed  PubMed Central  Google Scholar 

  • Pravetoni M, Comer SD (2019) Development of vaccines to treat opioid use disorders and reduce incidence of overdose. Neuropharmacology:107662

    Google Scholar 

  • Preller KH et al (2017) The fabric of meaning and subjective effects in LSD-induced states depend on serotonin 2A receptor activation. Curr Biol 27(3):451–457

    Article  CAS  PubMed  Google Scholar 

  • Raby WN et al (2009) Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence. Am J Addict 18(4):301–308

    Article  PubMed  PubMed Central  Google Scholar 

  • Ren Y et al (2009) Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci 29(47):14764–14769

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Robinson A, Wermeling DP (2014) Intranasal naloxone administration for treatment of opioid overdose. Am J Health Syst Pharm 71(24):2129–2135

    Article  CAS  PubMed  Google Scholar 

  • Ryan KK et al (2012) Physiological responses to acute psychological stress are reduced by the PPARgamma agonist rosiglitazone. Endocrinology 153(3):1279–1287

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Saitz R et al (2008) The case for chronic disease management for addiction. J Addict Med 2(2):55–65

    Article  PubMed  PubMed Central  Google Scholar 

  • Salehi M et al (2011) Importance of gabapentin dose in treatment of opioid withdrawal. J Clin Psychopharmacol 31(5):593–596

    Article  CAS  PubMed  Google Scholar 

  • Sanders NC et al (2013) Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. Exp Clin Psychopharmacol 21(4):294–302

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sandweiss AJ, Vanderah TW (2015) The pharmacology of neurokinin receptors in addiction: prospects for therapy. Subst Abuse Rehabil 6:93–102

    PubMed  PubMed Central  Google Scholar 

  • Sarruf DA et al (2009) Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 150(2):707–712

    Article  CAS  PubMed  Google Scholar 

  • Savage C, McCabe OL (1973) Residential psychedelic (LSD) therapy for the narcotic addict. A controlled study. Arch Gen Psychiatry 28(6):808–814

    Article  CAS  PubMed  Google Scholar 

  • Saxon AJ et al (2013) Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend 128(1–2):71–76

    Article  CAS  PubMed  Google Scholar 

  • Scavone JL, Sterling RC, Van Bockstaele EJ (2013) Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience 248:637–654

    Article  CAS  PubMed  Google Scholar 

  • Schjerning O et al (2016) Abuse potential of pregabalin: a systematic review. CNS Drugs 30(1):9–25

    Article  CAS  PubMed  Google Scholar 

  • Schlosburg JE et al (2013) Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci U S A 110(22):9036–9041

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schroeder JR et al (2018) Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder. Psychopharmacology (Berl) 235(10):2957–2966

    Article  CAS  Google Scholar 

  • Sigmon SC et al (2016) Interim buprenorphine vs. waiting list for opioid dependence. N Engl J Med 375(25):2504–2505

    Article  PubMed  PubMed Central  Google Scholar 

  • Smith L et al (2017) Probuphine (buprenorphine) subdermal implants for the treatment of opioid-dependent patients. P T 42(8):505–508

    PubMed  PubMed Central  Google Scholar 

  • Sobey PW et al (2003) The use of tramadol for acute heroin withdrawal: a comparison to clonidine. J Addict Dis 22(4):13–25

    Article  PubMed  Google Scholar 

  • Stimmel B, Kreek MJ (2000) Neurobiology of addictive behaviors and its relationship to methadone maintenance. Mt Sinai J Med 67(5–6):375–380

    CAS  PubMed  Google Scholar 

  • Strang J et al (2016) Naloxone without the needle – systematic review of candidate routes for non-injectable naloxone for opioid overdose reversal. Drug Alcohol Depend 163:16–23

    Article  CAS  PubMed  Google Scholar 

  • Strong CE, Kabbaj M (2018) On the safety of repeated ketamine infusions for the treatment of depression: effects of sex and developmental periods. Neurobiol Stress 9:166–175

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Tanum L et al (2017) Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence: a randomized clinical noninferiority trial. JAMA Psychiatry 74(12):1197–1205

    Article  PubMed  PubMed Central  Google Scholar 

  • Taylor CP, Angelotti T, Fauman E (2007) Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 73(2):137–150

    Article  CAS  PubMed  Google Scholar 

  • Tenney RD et al (2019) Vaccine blunts fentanyl potency in male rhesus monkeys. Neuropharmacology 158:107730

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Terry SF (2015) Obama’s precision medicine initiative. Genet Test Mol Biomarkers 19(3):113–114

    Article  PubMed  PubMed Central  Google Scholar 

  • Tomasino V et al (2001) The Key Extended Entry Program (KEEP): a methadone treatment program for opiate-dependent inmates. Mt Sinai J Med 68(1):14–20

    CAS  PubMed  Google Scholar 

  • Vashchinkina E et al (2018) Addiction-related interactions of pregabalin with morphine in mice and humans: reinforcing and inhibiting effects. Addict Biol 23(3):945–958

    Article  CAS  PubMed  Google Scholar 

  • Volkow ND, Collins FS (2017) The role of science in addressing the opioid crisis. N Engl J Med 377(4):391–394

    Article  PubMed  Google Scholar 

  • Volkow ND et al (2018) Prevention and treatment of opioid misuse and addiction: a review. JAMA Psychiatry 76(2):208–216

    Article  PubMed  Google Scholar 

  • Walsh SL et al (2013) Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers. Addict Biol 18(2):332–343

    Article  CAS  PubMed  Google Scholar 

  • Walsh SL et al (2017) Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial. JAMA Psychiatry 74(9):894–902

    Article  PubMed  PubMed Central  Google Scholar 

  • Watkins LR et al (2005) Glia: novel counter-regulators of opioid analgesia. Trends Neurosci 28(12):661–669

    Article  CAS  PubMed  Google Scholar 

  • Watkins LR et al (2007) “Listening” and “talking” to neurons: implications of immune activation for pain control and increasing the efficacy of opioids. Brain Res Rev 56(1):148–169

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wee S, Koob GF (2010) The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl) 210(2):121–135

    Article  CAS  Google Scholar 

  • Weiss RD et al (2011) Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 68(12):1238–1246

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • White J et al (2009) Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend 103(1–2):37–43

    Article  CAS  PubMed  Google Scholar 

  • WHO (2019) https://www.who.int/substance_abuse/information-sheet/en/

  • Williams AR et al (2018) Developing an opioid use disorder treatment cascade: a review of quality measures. J Subst Abuse Treat 91:57–68

    Article  PubMed  PubMed Central  Google Scholar 

  • Woody GE et al (2008) Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA 300(17):2003–2011

    Article  PubMed  PubMed Central  Google Scholar 

  • Woolley JD et al (2016) The effects of intranasal oxytocin in opioid-dependent individuals and healthy control subjects: a pilot study. Psychopharmacology (Berl) 233(13):2571–2580

    Article  CAS  Google Scholar 

  • Yamaori S et al (2011a) Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos 39(11):2049–2056

    Article  CAS  PubMed  Google Scholar 

  • Yamaori S et al (2011b) Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci 88(15–16):730–736

    Article  CAS  PubMed  Google Scholar 

  • Zhao Q et al (2016) The antidepressant-like effects of pioglitazone in a chronic mild stress mouse model are associated with PPARgamma-mediated alteration of microglial activation phenotypes. J Neuroinflammation 13(1):259

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  • Zorumski CF, Izumi Y, Mennerick S (2016) Ketamine: NMDA receptors and beyond. J Neurosci 36(44):11158–11164

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zuardi AW (2008) Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Braz J Psychiatry 30(3):271–280

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, NYU School of Medicine, New York, NY, USA

    Esther Blessing & John Rotrosen

  2. Department of Psychiatry, Maimonides Medical Center, Brooklyn, NY, USA

    Sanya Virani

Authors
  1. Esther Blessing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sanya Virani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John Rotrosen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Esther Blessing .

Editor information

Editors and Affiliations

  1. Wake Forest School of Medicine, Winston-Salem, NC, USA

    Michael A. Nader

  2. Addiction Institute of Mount Sinai, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Yasmin L. Hurd

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Blessing, E., Virani, S., Rotrosen, J. (2019). Clinical Trials for Opioid Use Disorder. In: Nader, M., Hurd, Y. (eds) Substance Use Disorders. Handbook of Experimental Pharmacology, vol 258. Springer, Cham. https://doi.org/10.1007/164_2019_304

Download citation

Publish with us

Policies and ethics

Search

Navigation